Immunological aspects of papillary thyroid cancer. What's new?
https://doi.org/10.14341/ket12695
Abstract
Studying of the common links of pathogenesis of endocrine, autoimmune and oncological diseases is the area of interest of researchers from all countries of the world. Comprehension of artificially created mutual influences of molecular-genetic, immune factors that underlie the development and progression of endocrine tumors, primarily thyroid cancer, is important for creation and application of innovative treatment methods in oncoendocrinology.
Today, the question of considering autoimmune diseases as a potential cause of oncological processes or on the contrary to consider them as protective conditions in some types of malignant tumors, remains controversial.
In particular, autoimmune thyropathies and papillary thyroid cancer is an interesting model for studying these complex relationships. . The purpose of this article is to discuss accumulated experience, review the literature devoted to the study of immunological aspects in the pathogenesis of papillary thyroid cancer, reconsider obtained material and form a conclusion.
About the Authors
Ekaterina A. Troshina
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
MD, PhD, Professor; eLibrary SPIN: 8821-8990
Moscow
Competing Interests:
not
Maria A. Terekhova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Student; eLibrary SPIN: 1619-0505
Moscow
Competing Interests:
not
Ravida R. Akhmatova
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
eLibrary SPIN:5238-9956
Moscow
Competing Interests:
not
References
1. Kachko VA. Klinicheskie, immunologicheskie i geneticheskie faktory prognoza vysokodifferencirovannogo raka shhitovidnoj zhelezy. [dissertation]. Moskva; 2006. (In Russ.). Доступно по: https:// www.endocrincentr.ru/specialists/science/dissertacionnyy-sovet/dissertacii/klinicheskie-immunologicheskie-i-geneticheskie-faktory-prognoza.
2. Ehlers M, Schott M. Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked? Trends Endocrinol Metab. 2014;25(12):656-664. doi: https://doi.org/10.1016/j.tem.2014.09.001
3. Nagayama Y. Thyroid Autoimmunity and Thyroid Cancer — The Pathogenic Connection: A 2018 Update. Horm Metab Res. 2018;50(12):922-931. doi: https://doi.org/10.1055/a-0648-4593
4. Borrello I, Imus PH. BCMA CAR T cells: the winding path to success. JClin Invest. 2019;129(6):2175-2177. doi: https://doi.org/10.1172/JCI128372
5. Giannini R, Moretti S, Ugolini C, et al. Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like. J Clin Endocrinol Metab. 2019;104(8):3557-3575. doi: https://doi.org/10.1210/jc.2018-01167
6. Han SA, Jang JH, Won KY, et al. Prognostic value of putative cancer stem cell markers (CD24, CD44, CD133, and ALDH1) in human papillary thyroid carcinoma. Pathol Res Pract. 2017;213(8):956-963. doi: https://doi.org/10.1016/j.prp.2017.05.002
7. Xi C, Zhang GQ, Sun ZK, et al. Interleukins in Thyroid Cancer: From Basic Researches to Applications in Clinical Practice. Front Immunol. 2020;11:1124. doi: https://doi.org/10.3389/fimmu.2020.01124
8. Svaton M, Fiala O, Krakorova G, et al. Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib. Oncol Lett. 2020;20(2):1376-1382. doi: https://doi.org/10.3892/ol.2020.11663
9. Yang X, Sun J, Han J, et al. Iodine promotes thyroid cancer development via SPANXA1 through the PI3K/AKT signalling pathway. Oncol Lett. 2019;18(1):637-644. doi: https://doi.org/10.3892/ol.2019.10391
10. Ferrari SM, Fallahi P, Galdiero MR, et al. Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. Int J Mol Sci. 2019;20(18):4413. doi: https://doi.org/10.3390/ijms20184413
11. Troshina EA, Nikonova TV, Svitich OA. Autoimmunnyj poliglanduljarnyj sindrom vzroslyh. — M.: GEOTAR-Media; 2019 (in Russ.).
12. Bergdorf K, Ferguson DC, Mehrad M, et al. Papillary thyroid carcinoma behavior: clues in the tumor microenvironment. Endocr Relat Cancer. 2019;26(6):601-614. doi: https://doi.org/10.1530/ERC-19-0074
13. Kim EY, Kim WB, Chung JH, et al. Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study. Thyroid. 2018;28(3):340-348. doi: https://doi.org/10.1089/thy.2017.0356.
14. O'Brien JM. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78-84. Surv Ophthalmol. 2000;45(2):167-168. doi: https://doi.org/10.1016/s0039-6257(00)00165-x
15. Na KJ, Choi H. Immune landscape of papillary thyroid cancer and immunotherapeutic implications. Endocr Relat Cancer. 2018;25(5):523-531. doi: https://doi.org/10.1530/ERC-17-0532
16. Cirello V, Fugazzola L. Novel insights into the link between fetal cell microchimerism and maternal cancers. J Cancer Res Clin Oncol. 2016;142(8):1697-1704. doi: https://doi.org/10.1007/s00432-015-2110-3
17. Cirello V, Fugazzola L. Positive effect of fetal cell microchimerism on tumor presentation and outcome in papillary thyroid cancer. Chimerism. 2014;5(3-4):106-108. doi: https://doi.org/10.1080/19381956.2015.1107254
18. Zyablov EV, Chesnokov NP, Barsukov VYu. Thyroid cancer: modern concepts of etiology and pathogenesis. Nauchnoe obozrenie. Meditsinskie nauki. 2016;3:37-61 (in Russ.).
19. Zhang P, Zhang H, Dong W, et al. IL-34 is a potential biomarker for the treatment of papillary thyroid cancer. J Clin Lab Anal. 2020;34(8):e23335. doi: https://doi.org/10.1002/jcla.23335
Review
For citations:
Troshina E.A., Terekhova M.A., Akhmatova R.R. Immunological aspects of papillary thyroid cancer. What's new? Clinical and experimental thyroidology. 2020;16(4):14-18. (In Russ.) https://doi.org/10.14341/ket12695
Views:
732
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
